$14.56
2.02% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock price

$14.56
+2.93 25.19% 1M
+6.18 73.75% 6M
+6.46 79.75% YTD
+9.68 198.36% 1Y
+8.62 145.12% 5Y
-10.54 41.99% 10Y
-0.44 2.93% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.30 2.02%
ISIN
US21900C3088
Symbol
CRMD
Sector

Key metrics

Market capitalization $987.53m
Enterprise Value $910.03m
P/E (TTM) P/E ratio 60.67
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.02
P/S ratio (TTM) P/S ratio 11.96
P/B ratio (TTM) P/B ratio 8.58
Revenue (TTM) Revenue $82.55m
EBIT (operating result TTM) EBIT $14.47m
Free Cash Flow (TTM) Free Cash Flow $-13.63m
Cash position $77.50m
EPS (TTM) EPS $0.24
P/E forward 29.12
P/S forward 6.85
EV/Sales forward 6.31
Short interest 12.73%
Show more

Is CorMedix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

CorMedix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CorMedix Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a CorMedix Inc forecast:

Buy
100%

Financial data from CorMedix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
83 83
-
100%
- Direct Costs 3.97 3.97
384% 384%
5%
79 79
9,684% 9,684%
95%
- Selling and Administrative Expenses 58 58
34% 34%
70%
- Research and Development Expense 6.30 6.30
40% 40%
8%
15 15
127% 127%
18%
- Depreciation and Amortization 0.45 0.45
543% 543%
1%
EBIT (Operating Income) EBIT 14 14
126% 126%
18%
Net Profit 17 17
134% 134%
21%

In millions USD.

Don't miss a Thing! We will send you all news about CorMedix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CorMedix Inc Stock News

Positive
Seeking Alpha
9 days ago
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis mar...
Positive
Seeking Alpha
10 days ago
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst su...
Neutral
GlobeNewsWire
15 days ago
BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025.
More CorMedix Inc News

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Joseph Todisco
Employees 65
Founded 2006
Website cormedix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today